Read by QxMD icon Read


Inge Werner, Annette Aldrich, Benjamin Becker, Dennis Becker, Markus Brinkmann, Michael Burkhardt, Norbert Caspers, Sophie Campiche, Nathalie Chèvre, Rolf-Alexander Düring, Beate I Escher, Fabian Fischer, Sabrina Giebner, Katharina Heye, Henner Hollert, Marion Junghans, Cornelia Kienle, Katja Knauer, Muris Korkaric, Veronika Märkl, Jane Muncke, Jörg Oehlmann, Georg Reifferscheid, Daniel Rensch, Andreas Schäffer, Sabrina Schiwy, Simon Schwarz, Helmut Segner, Eszter Simon, Rita Triebskorn, Etiënne L M Vermeirssen, Thomas Wintgens, Markus Zennegg
This report provides a brief review of the 20th annual meeting of the German Language Branch of the Society of Environmental Toxicology and Chemistry (SETAC GLB) held from September 7th to 10th 2015 at ETH (Swiss Technical University) in Zurich, Switzerland. The event was chaired by Inge Werner, Director of the Swiss Centre for Applied Ecotoxicology (Ecotox Centre) Eawag-EPFL, and organized by a team from Ecotox Centre, Eawag, Federal Office of the Environment, Federal Office of Agriculture, and Mesocosm GmbH (Germany)...
2016: Environmental Sciences Europe
Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V Sequist, Mark M Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi
BACKGROUND: Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting. The anti-PD-1 antibody pembrolizumab has shown efficacy as monotherapy in patients with advanced NSCLC and has a non-overlapping toxicity profile with chemotherapy. We assessed whether the addition of pembrolizumab to platinum-doublet chemotherapy improves efficacy in patients with advanced non-squamous NSCLC...
October 10, 2016: Lancet Oncology
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer
Background Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). Methods In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy...
October 8, 2016: New England Journal of Medicine
Christopher G Parkin, Anita Homberg, Rolf Hinzmann
International experts in the field of diabetes and diabetes technology met in Madrid, Spain, for the 9th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts, thus facilitating new collaborations and research projects to improve the lives of people with diabetes. The 2016 meeting comprised a comprehensive scientific program, parallel interactive workshops, and two keynote lectures.
October 6, 2016: Diabetes Technology & Therapeutics
Leila Khoja, Minnie Kibiro, Ur Metser, Craig Gedye, David Hogg, Marcus O Butler, Eshetu G Atenafu, Anthony M Joshua
BACKGROUND: Radiological assessment of response to checkpoint inhibitors remains imperfect. We evaluated individual lesion and inter-patient response by response evaluation (RECIST) 1.1, immune-related response criteria (irRC), CHOI and modified CHOI (mCHOI) and correlated response with overall survival (OS). METHODS: Thirty-seven patients with 567 measurable lesions treated with pembrolizumab in the Keynote 001 trial were studied. Association of response with OS was determined...
October 4, 2016: British Journal of Cancer
Elizabeth A Nardi, Lisa Korin Lentz, Katherine Winckworth-Prejsnar, Amy P Abernethy, Robert W Carlson
When used effectively, health information technology (HIT) can transform clinical care and contribute to new research discoveries. Despite advances in HIT and increased electronic health record adoption, many challenges to optimal use, interoperability, and data sharing exist. Data standardization across systems is limited, and scanned medical note documents result in unstructured data that make reporting on quality measures for reimbursement burdensome. Different policies and initiatives, including the Health Information Technology for Economic and Clinical Health Act, the Medicare Access and CHIP Reauthorization Act, and the National Cancer Moonshot initiative, among others, all recognize the impact that HIT can have on cancer care...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Hideyuki Akaza, Yoshihiko Hirao, Choung-Soo Kim, Mototsugu Oya, Seiichiro Ozono, Dingwei Ye, Matthew Cooperberg, Shiro Hinotsu, Ji Youl Lee, Gang Zhu, Mikio Namiki, Shigeo Horie, Byung Ha Chung, Chung-Hsin Chen, Ng Chi Fai, Lukman Hakim, Edmund Chiong, Jason Letran, Rainy Umbas, Kazuhiro Suzuki, Kazuo Nishimura, Teng Aik Ong, Bannakij Lojanapiwat, Tong-Lin Wu, Wun-Jae Kim, Declan Murphy, Osamu Ogawa, Peter Carroll, Seiji Naito, Taiji Tsukamoto
The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the course of 2 years. The A-CaP Study is scheduled to begin in 2016, when each participating country or region will begin registration of newly diagnosed prostate cancer patients and conduct prognosis investigations. From the data gathered, common research themes will be identified, such as comparisons among Asian countries of background factors in newly diagnosed prostate cancer patients. This is the first Asia-wide study of prostate cancer and has developed from single country research efforts in this field, including in Japan and Korea...
September 2016: Prostate International
Andrew B Rosenkrantz, C Matthew Hawkins
PURPOSE: The aim of this study was to evaluate the feasibility of using Twitter polls to assess public opinion regarding session content at a national specialty society meeting. METHODS: Twitter polls allow users to embed multiple-choice questions within tweets and automatically aggregate responses. Two radiologists attending the 2016 annual meeting of the ACR posted a Twitter poll containing the hashtag #ACR2016 during 10 meeting sessions addressing socioeconomics/advocacy, patient experience, and social media/informatics (20 polls total)...
September 24, 2016: Journal of the American College of Radiology: JACR
Jorge Hernández de Anda
The 14th Symposium of the International Society for Veterinary Epidemiology and Economics (ISVEE 14) was held in Merida, Yucatan, Mexico during 3-7 November. 2015. The purpose of ISVEE 14 Yucatan 2015 was to provide a global forum for graduate students, postdoctoral fellows, junior and senior investigators, as well as health policymakers to exchange information that can advance the fields of veterinary epidemiology and economics, and other disciplines in the health and social sciences. The main theme of ISVEE 14 was Planning Our Future...
September 20, 2016: Preventive Veterinary Medicine
Gilberto De Lima Lopes, Yi-Long Wu, Sara Sadowski, Jin Zhang, Reshma Rangwala, Debra Kush, Tony Mok
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Roy S Herbst, Paul Baas, Jose L Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary Jo Fidler, Veerle Surmont, Gilberto De Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B Garon
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Suresh Ramalingam, Rina Hui, Leena Gandhi, Enric Carcereny, Enriqueta Felip, Myung-Ju Ahn, Joseph P Eder, Ani S Balmanoukian, Natasha Leighl, Charu Aggarwal, Leora Horn, Amita Patnaik, Gary W Middleton, Matthew Gubens, Matthew Hellmann, Jean-Charles Soria, Gregory M Lubiniecki, Jin Zhang, Bilal Piperdi, Edward B Garon
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Roy S Herbst, Paul Baas, Jose L Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary Jo Fidler, Veerle Surmont, Gilberto De Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B Garon
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Astrid M Roy-Engel
The Tenth International Conference on Transcription by RNA Polymerases I, III, IV and V (the 'Odd Pols') was held June 24-28, 2016 at the University of Michigan, Ann Arbor, USA and organized by David Engelke, Deborah Johnson, Richard Maraia, Lawrence Rothblum, David Schneider, Andrzej Wierzbicki and Astrid Engel. The organizers are grateful for the support from the Rackham Graduate School of the University of Michigan for providing the meeting venue. The environment provided a great background with unexpected encounters with fireflies, free live music and a festive fireworks display...
September 21, 2016: Gene
Atsushi Tanaka, Xiong Ma, Osamu Yokosuka, Martin Weltman, Hong You, Deepak N Amarapurkar, Yoon Jun Kim, Zaigham Abbas, Diana A Payawal, Ming-Ling Chang, Cumali Efe, Ersan Ozaslan, Masanori Abe, Robert Mitchell-Thain, Mikio Zeniya, Kwang Hyub Han, John M Vierling, Hajime Takikawa
During the 25th annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL 2016) in Tokyo, we organized and moderated an inaugural satellite symposium on the autoimmune liver diseases, autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). Following the keynote lecture by John M. Vierling (USA), speakers from the Asia-Pacific region provided an up-to-date perspective on the epidemiology, clinical practice and research in AIH and PBC in the Asia-Pacific region. Although epidemiology and clinical features of AIH seem to be similar in East Asia compared to those in western countries, the majority of patients with AIH are detected at an advanced stage and have higher mortality rates in South Asia, indicating an unmet need for earlier diagnosis and the initiation of appropriate immunosuppressive treatment...
September 20, 2016: Hepatology International
Laura Q M Chow, Robert Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph Paul Eder, Barbara Burtness, Se-Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia-Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled-Filhart, Kumudu Pathiraja, Jonathan D Cheng, Tanguy Y Seiwert
PURPOSE: Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported...
September 19, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
(no author information available yet)
No abstract text is available yet for this article.
September 2016: Nephrology
K Ousey, R Webb
Earlier this year the University of Huddersfield's Institute of Skin Integrity and Infection Prevention in association with the Journal of Wound Care (JWC) held the first International Skin Integrity and Infection Prevention Conference. The 2-day event consisted of a mix of keynotes, symposia and short presentations from key opinion leaders and post graduate research students. Here Professor Karen Ousey and Dr Rachel Webb present the highlights of this event.
September 2016: Journal of Wound Care
Matthew B McCarra, Robert L Owens
No abstract text is available yet for this article.
July 2016: Journal of Thoracic Disease
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Caroline Robert, Omid Hamid, Adil Daud, Alfons van den Eertwegh, Lee Cranmer, Steven O'Day, Igor Puzanov, Jacob Schachter, Christian Blank, April Salama, Carmen Loquai, Janice M Mehnert, Darcy Hille, Scot Ebbinghaus, S Peter Kang, Wei Zhou, Antoni Ribas
BACKGROUND: In KEYNOTE-002, pembrolizumab significantly prolonged progression-free survival and was associated with a better safety profile compared with chemotherapy in patients with advanced melanoma that progressed after ipilimumab. We present health-related quality of life (HRQoL) outcomes from KEYNOTE-002. METHODS: Patients were randomly assigned 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or investigator-choice chemotherapy. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 instrument...
November 2016: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"